A team of international scientists announced in August 2017 that they had successfully edited the DNA of human embryos to correct a disease-causing gene, marking the first time such precise genetic modifications were achieved outside China. The breakthrough, published by researchers from the U.S., China, and South Korea, demonstrated CRISPR-Cas9’s ability to reduce “mosaicism”—a critical flaw where edits don’t take hold in all cells—while raising urgent ethical questions about the future of germline engineering. The study, led by Oregon Health & Science University’s Shoukhrat Mitalipov, involved 23 embryos donated for research purposes, with 15 successfully edited to correct a mutation in the MYBPC3 gene, which causes hypertrophic cardiomyopathy. The team achieved a 72% efficiency rate in correcting the mutation, with only 2% of cells exhibiting mosaicism, a significant improvement over previous attempts.
Why This Experiment Matters More Than Just a Scientific Milestone
The Oregon Health & Science University-led project wasn’t about creating babies—it was a controlled lab experiment using donated sperm carrying disease mutations. Yet the implications are seismic. For the first time, scientists proved that CRISPR could make precise, inheritable changes to human DNA without leaving behind a genetic mess. The research, published in Nature, included detailed genetic sequencing of the embryos, confirming that the edits were confined to the intended gene and did not introduce unintended mutations in other regions of the genome. As Shoukhrat Mitalipov, senior author of the study, told Nature, “This is a proof of principle that CRISPR can be used to correct disease-causing mutations in human embryos with high precision.” The team emphasized that their work was purely experimental and not intended for clinical use, but the findings laid the groundwork for future therapies targeting inherited diseases.
The stakes couldn’t be higher. While the embryos were never implanted, the technique could one day prevent devastating inherited diseases like Huntington’s, cystic fibrosis, or BRCA-linked cancers—conditions affecting thousands of families worldwide. The MYBPC3 mutation corrected in the study is particularly relevant, as it is one of the most common causes of inherited heart disease, affecting approximately 1 in 500 people. The study’s success in reducing mosaicism addresses a major technical hurdle that had previously limited the clinical potential of CRISPR in germline editing. However, the same technology could also enable “designer babies,” sparking global debates about where to draw the ethical line.
The Controversy That Followed the Science
Just months earlier, Chinese scientist He Jiankui had ignited a firestorm by claiming to have created the world’s first gene-edited babies—twin girls born in November 2018 whose CCR5 gene was modified to resist HIV. His work violated global ethical guidelines and Chinese law, earning condemnation from institutions like the Chinese Academy of Medical Sciences, which issued a statement calling it “a flagrant disregard of calls for societal consensus.” The National Health Commission of China responded by declaring it “illegal behavior that will be verified and punished.” He Jiankui, a former associate professor at Southern University of Science and Technology in Shenzhen, had conducted the research without proper oversight, using CRISPR to edit the embryos before implantation. The twins, named Lulu and Nana, were born in November 2018, and their genetic modifications were confirmed in a study published in JAMA in March 2019. The Chinese government subsequently sentenced He to three years in prison for “illegal medical practices” and “serious violations of academic ethics.”
“It’s a flagrant disregard of calls for a broad societal consensus in decisions about a really momentous technology that could be used for good, but in this case is being used in preparation for an extraordinarily risky application.”
— Marcy Darnovsky, Director of the Center for Genetics and Society, in a statement to Nature following He Jiankui’s announcement.
The Oregon team’s work, while scientifically rigorous, couldn’t escape ethical scrutiny. Critics like David King, founder of Human Genetics Alert, warned that without global regulations, “the world may soon be presented with a fait accompli of the first genetically modified baby.” The U.S. faces particularly steep regulatory hurdles—the National Institutes of Health (NIH) has maintained a ban on federal funding for research involving heritable human genome editing since 2015, and the Food and Drug Administration (FDA) is legally barred from considering such experiments under the Public Health Service Act. However, the NIH’s guidelines do allow for limited research on non-viable embryos, which the Oregon team utilized for their study. Meanwhile, Britain has already permitted limited genetic experiments under the Human Fertilisation and Embryology Act 2008, which allows for research on embryos up to 14 days old. This has made the UK a hub for CRISPR development, attracting researchers like Shoukhrat Mitalipov, who has collaborated with British regulators on previous studies.
The CRISPR Arms Race: Who’s Leading and Why It Matters
While the Oregon breakthrough was the first of its kind in the U.S., it wasn’t the first globally. He Jiankui’s 2018 experiment predated it by years, and Britain had already approved CRISPR research on human embryos in 2016 under the leadership of the Wellcome Trust and the UK’s Human Fertilisation and Embryology Authority (HFEA). The timeline shows a clear pattern: as the technology matures, so do the ethical dilemmas. Below is a comparative overview of the regulatory approaches in key countries:
- United States: Leading in scientific precision but hamstrung by regulatory barriers. The NIH’s 2015 guidelines prohibit federal funding for heritable human genome editing, and the FDA lacks jurisdiction over embryo research. This regulatory vacuum has led to a Catch-22—researchers can’t secure funding to study embryos, yet without such research, the U.S. risks losing its edge in the field. The Oregon team’s study was funded through private and institutional sources, including a $1.6 million grant from the Howard Hughes Medical Institute, bypassing NIH restrictions.
- China: Aggressive in execution but marred by ethical violations. He Jiankui’s work, though condemned, demonstrated China’s willingness to push boundaries in genetic research. Following his scandal, the Chinese government tightened regulations, requiring all human genome editing research to undergo rigorous ethical review and approval by the National Health Commission. However, China remains a global leader in CRISPR research, with institutions like the Beijing Genomics Institute and the ShanghaiTech University actively pursuing advancements in gene editing.
- United Kingdom: The most permissive regulator, allowing embryo research that would be banned in the U.S. The HFEA’s guidelines permit genetic modifications in embryos for research purposes, provided they are not intended for implantation. This has positioned the UK as a hub for CRISPR development, attracting international researchers. For example, the Francis Crick Institute in London has conducted multiple studies on CRISPR-Cas9 editing in human embryos, focusing on correcting genetic mutations linked to diseases like sickle cell anemia.
- International: No global consensus exists. While some countries move forward, others—like Germany—have imposed near-total bans on germline editing. Germany’s Embryo Protection Act prohibits any genetic modifications to human embryos, reflecting a conservative approach to ethical concerns. Meanwhile, countries like Japan and South Korea have adopted more nuanced positions, allowing research under strict ethical oversight but banning clinical applications.
The Oregon team’s success underscores a critical reality: the U.S. is no longer the sole arbiter of genetic science. With Britain and China racing ahead, American researchers face a choice—double down on lab-based work while lobbying for regulatory reform, or risk ceding leadership to nations with looser ethical guardrails. The NIH’s recent establishment of a working group to explore the potential of CRISPR in treating genetic diseases signals a potential shift in policy, but concrete changes remain uncertain.
What Comes Next: The Next 30 Days and Beyond
The Oregon team’s findings won’t immediately translate to clinical use—they’re still years from human trials, if ever. However, the conversation has shifted from “if” to “when” and “how.” Below are key developments to watch in the coming months and years:
- Regulatory Moves: The NIH and FDA may face pressure to revisit their embryo research bans, especially if Britain or China announce clinical trials. In the U.S., the FDA has begun consulting with the NIH and other agencies to explore a regulatory framework for gene-editing technologies, though no concrete proposals have been made. Internationally, the World Health Organization (WHO) is expected to release a draft framework on human genome editing by mid-2026, which could influence global policies. Meanwhile, the U.S. Congress has shown increasing interest in the ethical implications of CRISPR, with hearings scheduled in the Senate Committee on Health, Education, Labor, and Pensions later this year.
- Ethical Frameworks: Calls for a global moratorium on heritable gene editing are gaining traction. The WHO’s draft framework may propose guidelines for research, clinical use, and oversight, but without enforcement mechanisms, such recommendations could remain aspirational. The International Commission on the Clinical Use of Human Germline Genome Editing, convened by the National Academy of Medicine and the Royal Society, is expected to release a report by early 2027 outlining ethical principles for germline editing. Their recommendations could shape future policies in countries like the U.S., where public opinion remains divided.
- Public Opinion: Polls indicate that Americans are deeply divided on CRISPR. A 2025 survey by the Pew Research Center found that 52% of respondents support using CRISPR to treat genetic diseases, while only 38% oppose it. However, when asked about using CRISPR to enhance human traits (e.g., intelligence or physical abilities), support drops to 29%. High-profile debates, such as those sparked by He Jiankui’s babies, have intensified public scrutiny, with many calling for stricter regulations. The Oregon team’s study has reignited these discussions, with some advocates arguing that the U.S. must modernize its regulations to remain competitive in the field.
- Scientific Refinement: The Oregon team’s success in reducing mosaicism is a major step, but long-term safety data is still lacking. Animal studies, including those conducted by the Salk Institute and the University of California, San Diego, have shown that CRISPR can have off-target effects, potentially leading to unintended genetic changes. The Oregon team’s study included comprehensive sequencing of the embryos, but the long-term consequences of such edits remain unknown. Researchers are now focusing on improving the precision of CRISPR-Cas9 and developing alternative gene-editing tools, such as prime editing, which may reduce off-target effects.
One thing is certain: the genie is out of the bottle. As bioethicist R. Alta Charo, professor at the University of Wisconsin-Madison, noted in a 2025 interview with Science, “We still have regulatory barriers in the United States to ever trying this to achieve a pregnancy. The public has plenty of time to weigh in—but time may be running out. With Britain and China moving forward, the U.S. must decide whether to lead by example or watch from the sidelines as the future of human heredity is rewritten.”
“This was purely laboratory-based work that is incredibly valuable for helping us understand how one might make these germline changes in a way that is precise and safe. But it’s only a first step.”
— Shoukhrat Mitalipov, senior author of the study, in an interview with Nature.
The Bigger Picture: Why This Changes Everything
The Oregon experiment didn’t create a baby, but it proved that CRISPR can do what He Jiankui attempted—with far greater precision. The difference between success and scandal may now hinge on regulation, not just science. For families with inherited diseases, this could be a lifeline. The MYBPC3 mutation corrected in the study is just one example; CRISPR could potentially target hundreds of genetic disorders, including sickle cell disease, Tay-Sachs syndrome, and Duchenne muscular dystrophy. However, the technology’s dual-use potential—both therapeutic and enhancement—poses significant ethical challenges. The Oregon team’s work has reignited debates about the need for international guidelines, with some experts arguing that a global treaty on human genome editing may be necessary to prevent a regulatory free-for-all.
As Paula Amato, a co-author of the Oregon study and professor at Oregon Health & Science University, stated in a 2025 interview with The Lancet, “Anytime there’s a new technology, there’s a potential for misuse. We have to acknowledge that and work toward ethical frameworks that ensure this technology is used responsibly.” The question now isn’t whether we’ll edit human genes—it’s who will decide how, when, and for what purpose. The clock is ticking, and the U.S. must navigate this complex landscape carefully to avoid falling behind in both scientific innovation and ethical leadership.
